Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of eriocalyxin to preparation of medicaments for treating autoimmune diseases

An autoimmune, calyxine technology, applied in allergic diseases, drug combinations, nervous system diseases, etc., can solve the problems of unreported application of calyxe

Active Publication Date: 2011-11-23
RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF4 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no report about the application of echinoceline in the preparation of drugs for the treatment of autoimmune and infectious diseases.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of eriocalyxin to preparation of medicaments for treating autoimmune diseases
  • Application of eriocalyxin to preparation of medicaments for treating autoimmune diseases
  • Application of eriocalyxin to preparation of medicaments for treating autoimmune diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0091] Example 1 Calyxin alleviates the condition of EAE in mice

[0092] (A) Treatment options:

[0093] Establish the EAE mouse model. After the onset of the disease (the 11th day after the establishment of the model), the mice were randomly divided into groups, and intraperitoneally injected with solvent (200 μl / mouse, solvent control group, n=8) or B. (administration group, n=10), the dose was 10 mg echinoceline / kg body weight, for 18 consecutive days, the state of the mice was observed every day, and clinical scores were made according to the degree of disease. The mice in the solvent control group all broke out the typical EAE condition, and the average highest clinical score reached 3.81±0.34, while the average highest clinical score in the treatment group was 2.80±0.29.

[0094] (B) Prevention program:

[0095] After the mice were randomly grouped, they were given solvent (200 μl / mouse, solvent control group, n=8) or echinacea (administration group, n=6) every day ...

Embodiment 2

[0097] Example 2 Pathological observation of the spinal cord of EAE mice after treatment with calyxin

[0098] (A) H&E staining

[0099] H&E tissue section staining was performed on the spinal cord lesions of the normal mice, EAE-onset mice in the solvent group and the drug-administered group. There was no inflammatory infiltration in normal mice, and there were a large number of inflammatory infiltration cells in the perivascular tissue of the spinal cord of the mice in the solvent group, while the inflammatory infiltration in the corresponding parts of the mice in the echinoceline B treatment group was significantly reduced.

[0100] (B) Luxol Fast Blue staining

[0101] For normal mice, EAE-onset mice in vehicle group and administration group, the spinal cord lesions were stained with Luxol Fast Blue myelin tissue sections. Normal mice had no demyelinating lesions, and the white matter part of the spinal cord of the mice in the solvent group was largely lost, and the va...

Embodiment 3

[0103] Example 3 Calyxin inhibits the proliferation and differentiation of autoantigen-specific T cells in EAE mice

[0104] Under the specific inflammatory microenvironment and corresponding antigen stimulation, naive CD4+ T cells are activated and differentiated into various helper T cells (Th) to mediate effector effects. Th1 and Th17 cells play a pathogenic role in the pathogenesis of EAE, and regulatory T cells (Treg) have an inhibitory effect on the pathogenesis of EAE. In order to reveal the mechanism of EriB in protecting EAE mice, we first detected the proliferative ability of the EriB-treated group and the solvent control group in mice stimulated against the self-antigen MOG at the peak of EAE. The results showed that normal mice were resistant to MOG No response; EriB splenocytes of the mice in the solvent group had strong proliferative responses to MOG stimulation; T cells in the peripheral lymphoid organs (spleen) of the mice treated with eriocalyxin were signif...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of eriocalyxin to the preparation of medicaments for treating autoimmune diseases and application of the eriocalyxin to the preparation of medicaments for treating infectious diseases. The invention has the advantages that a new medical purpose of the eriocalyxin is explored, and the new application field is developed for the eriocalyxin. The eriocalyxin is safe, non-toxic and obvious in medicinal effect, so a medicinal prospect is good; the eriocalyxin can inhibit the activation of a Janus kinase / signal tranducer and activator of transcription (JAK / STAT) conduction channel related to cell factors and inhibit the differentiation of Th1 and Th17 cells which have pathogenicity in experimental autoimmune encephalomyelitis (EAE) mice specifically, has the inhibitory effect on the abnormal activation of a nuclear factor-kappa binding (NF-kB) signal channel, changes the inflammatory gene transcription of inflammation microenvironment components, and inhibits the EAE diseases of adoptive transplanted mice so as to play the effective roles of treating and preventing the EAE mice. The study indicates that the eriocalyxin has good medicinal prospects of treating the autoimmune diseases and the infectious diseases.

Description

technical field [0001] The invention relates to the application of a traditional Chinese medicine extract, in particular, the application of eriophyllin in the preparation of medicines for treating autoimmune diseases. Background technique [0002] Autoimmune diseases and infectious diseases have similar pathogenesis, and both have out-of-control inflammatory responses. Multiple sclerosis (Multiple sclerosis, MS) is an autoimmune disease mainly involving the central nervous system. The onset of the disease often begins in young and middle-aged patients, and most patients will gradually become disabled with progressive neurological dysfunction, and the loss of working ability will bring a heavy economic burden to the family and society. The pathological feature of multiple sclerosis is the inflammatory infiltration of the central nervous system and the resulting white matter demyelination. The inflammatory response caused by the abnormal activation of autoantigen-reactive e...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/35A61P37/02A61P25/00A61P31/00A61P29/00
Inventor 陈赛娟陈竺卢瑛陈冰宋君红王佰言
Owner RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com